Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30822
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPedrini, Steve-
dc.contributor.authorDoecke, James D-
dc.contributor.authorHone, Eugene-
dc.contributor.authorWang, Penghao-
dc.contributor.authorThota, Rohith-
dc.contributor.authorBush, Ashley I-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorDoré, Vincent-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorAmes, David-
dc.contributor.authorRainey-Smith, Stephanie-
dc.contributor.authorVerdile, Giuseppe-
dc.contributor.authorSohrabi, Hamid R-
dc.contributor.authorRaida, Manfred R-
dc.contributor.authorTaddei, Kevin-
dc.contributor.authorGandy, Sam-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorChatterjee, Pratishtha-
dc.contributor.authorMartins, Ralph N-
dc.date2022-
dc.date.accessioned2022-09-06T06:51:12Z-
dc.date.available2022-09-06T06:51:12Z-
dc.date.issued2022-07-30-
dc.identifier.citationJournal of Neurochemistry 2022; 163(1): 53-67en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30822-
dc.description.abstractCholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low-Density Lipoprotein (LDL) cholesterol. On the other hand, High-Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL-functionality, which depends upon the HDL-cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL-cargo (Cholesterol, ApoA-I, ApoA-II, ApoC-I, ApoC-III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC-Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA-I ratio in AD and HC-Conv, as well as an increased ApoD/ApoA-I ratio and a decreased ApoA-II/ApoA-I ratio in AD. Higher cholesterol/ApoA-I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA-II/ApoA-I and ApoJ/ApoA-I ratios were associated with greater cortical grey matter volume (and for ApoA-II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status-independent manner, the ApoE/ApoA-I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.en
dc.language.isoeng-
dc.subjectAlzheimer's diseaseen
dc.subjectApoEen
dc.subjectHDLen
dc.subjectHDL-cargoen
dc.subjectamyloid-βen
dc.subjectcholesterolen
dc.titlePlasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Neurochemistryen
dc.identifier.affiliationUniversity of Melbourne Academic unit for Psychiatry of Old Age, St George's Hospital, Kew, Victoria, Australia..en
dc.identifier.affiliationAustralian E-Health Research Centre, CSIRO, Brisbane, Queensland, Australia..en
dc.identifier.affiliationSchool of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia..en
dc.identifier.affiliationCRC for Mental Health, Melbourne, Victoria, Australia..en
dc.identifier.affiliationCollege of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, Australia..en
dc.identifier.affiliationFaculty of Medicine, Health and Human Sciences, Department of Biomedical Sciences, Macquarie University, Sydney, New South Wales, Australia..en
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia..en
dc.identifier.affiliationCentre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia..en
dc.identifier.affiliationCurtin Medical School, Curtin University, Bentley, Western Australia, Australia..en
dc.identifier.affiliationCurtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia..en
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia..en
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australia..en
dc.identifier.affiliationDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania, USA..en
dc.identifier.affiliationLife Science Institute, Singapore Lipidomics Incubator, National University of Singapore, Singapore City, Singapore..en
dc.identifier.affiliationDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/36000528/en
dc.identifier.doi10.1111/jnc.15681en
dc.type.contentTexten
dc.identifier.orcidhttps://orcid.org/0000-0002-6409-8022en
dc.identifier.orcidhttps://orcid.org/0000-0003-2863-0293en
dc.identifier.orcidhttps://orcid.org/0000-0001-6708-3718en
dc.identifier.orcidhttps://orcid.org/0000-0002-0293-913Xen
dc.identifier.orcidhttps://orcid.org/0000-0001-8259-9069en
dc.identifier.orcidhttps://orcid.org/0000-0003-3910-2453en
dc.identifier.orcidhttps://orcid.org/0000-0002-8051-0558en
dc.identifier.orcidhttps://orcid.org/0000-0001-7328-9624en
dc.identifier.orcidhttps://orcid.org/0000-0003-2475-0124en
dc.identifier.orcidhttps://orcid.org/0000-0001-8017-8682en
dc.identifier.orcidhttps://orcid.org/0000-0002-8106-7957en
dc.identifier.orcidhttps://orcid.org/0000-0003-3072-7940en
dc.identifier.orcidhttps://orcid.org/0000-0003-4877-1958en
dc.identifier.orcidhttps://orcid.org/0000-0002-4828-9363en
dc.identifier.orcidhttps://orcid.org/0000-0002-5832-9875en
dc.identifier.pubmedid36000528-
local.name.researcherDoré, Vincent
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

82
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.